Chimeric Antigen Receptor T Cell Therapy in Hematology
Chimeric Antigen Receptor T Cell Therapy in Hematology
复制标题
DOI：
10.4274/tjh.2015.0049
复制
发表时间：
2015-01-01
影响因子：
2.6
通讯作者：
Arslan, Onder
中科院分区：
文献类型：
--
作者：
Ataca, Pinar;Arslan, Onder
免疫系统可以控制和消除癌细胞。免疫介导的肿瘤细胞消除已经被发现，并且是癌症疫苗和包括造血干细胞移植的细胞疗法的基础。免疫性T细胞转移已被改进为更特异和有效，并导致更少的脱靶毒性。目前，有两种形式的工程T细胞正在临床试验中进行测试：T细胞受体（TCR）和嵌合抗原受体（CAR）修饰的T细胞。2014年7月1日，美国食品和药物管理局授予抗CD19 CAR T细胞疗法“突破性疗法”称号。进行了许多研究来评估这种令人兴奋和有效的新治疗方式的益处。本文综述了过继免疫治疗的历史，使用汽车的过继免疫治疗，CAR的制造过程，临床前和临床研究，以及这种策略的有效性和缺点。
It is well demonstrated that the immune system can control and eliminate cancer cells. Immune-mediated elimination of tumor cells has been discovered and is the basis of both cancer vaccines and cellular therapies including hematopoietic stem cell transplantation. Adoptive T cell transfer has been improved to be more specific and potent and to cause less off-target toxicity. Currently, there are two forms of engineered T cells being tested in clinical trials: T cell receptor (TCR) and chimeric antigen receptor (CAR) modified T cells. On 1 July 2014, the United States Food and Drug Administration granted 'breakthrough therapy' designation to anti-CD19 CAR T cell therapy. Many studies were conducted to evaluate the benefits of this exciting and potent new treatment modality. This review summarizes the history of adoptive immunotherapy, adoptive immunotherapy using CARS, the CAR manufacturing process, preclinical and clinical studies, and the effectiveness and drawbacks of this strategy.